

**Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE)  
Recombinant Antibody  
Catalog # APR10115****Specification**

---

**Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P15328</a>
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

**Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) - Additional Information****Target/Specificity**  
FOLR1 / FRA**Endotoxin**

< 0.001EU/ µg, determined by LAL method.

**Conjugation**

MMAE

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Storage**

-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

**Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) - Protein Information**

**Name** FOLR1

**Synonyms** FOLR

**Function**

Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells (PubMed: [19074442](http://www.uniprot.org/citations/19074442), PubMed: [23851396](http://www.uniprot.org/citations/23851396), PubMed: [23934049](http://www.uniprot.org/citations/23934049), PubMed: [2527252](http://www.uniprot.org/citations/2527252)), PubMed: [19074442](http://www.uniprot.org/citations/19074442), PubMed: [23851396](http://www.uniprot.org/citations/23851396), PubMed: [23934049](http://www.uniprot.org/citations/23934049), PubMed: [2527252](http://www.uniprot.org/citations/2527252)

href="http://www.uniprot.org/citations/8033114" target="\_blank">8033114</a>, PubMed:<a href="http://www.uniprot.org/citations/8567728" target="\_blank">8567728</a>). Has high affinity for folate and folic acid analogs at neutral pH (PubMed:<a href="http://www.uniprot.org/citations/23851396" target="\_blank">23851396</a>, PubMed:<a href="http://www.uniprot.org/citations/23934049" target="\_blank">23934049</a>, PubMed:<a href="http://www.uniprot.org/citations/2527252" target="\_blank">2527252</a>, PubMed:<a href="http://www.uniprot.org/citations/8033114" target="\_blank">8033114</a>, PubMed:<a href="http://www.uniprot.org/citations/8567728" target="\_blank">8567728</a>). Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release (PubMed:<a href="http://www.uniprot.org/citations/8567728" target="\_blank">8567728</a>). Required for normal embryonic development and normal cell proliferation (By similarity).

### Cellular Location

Cell membrane; Lipid-anchor, GPI-anchor Apical cell membrane; Lipid-anchor, GPI- anchor Basolateral cell membrane; Lipid-anchor, GPI-like-anchor. Secreted Cytoplasmic vesicle. Cytoplasmic vesicle, clathrin-coated vesicle. Endosome. Note=Endocytosed into cytoplasmic vesicles and then recycled to the cell membrane

### Tissue Location


Primarily expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum. Detected in placenta and thymus epithelium.

## Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


## Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) - Images



Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) is more than 95%, determined by SEC-HPLC.



Immobilized human FR $\alpha$  His at 2  $\mu\text{g/mL}$  can bind Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE)  $\square$  EC<sub>50</sub>=0.007651  $\mu\text{g/mL}$